ReviewChemical Society reviews2014
PET/SPECT imaging agents for neurodegenerative diseases.
Review in Chemical Society reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 181 citations in OpenAlex.
- Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Stable BFAngewandte Chemie (International ed. in English) · 2026Article
- Cognitive Assessment in Adults With Adrenal Cortisol Insufficiency: Challenges and Opportunities.Endocrine reviews · 2026Review
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- A fluorescent probe for concurrent detection of cysteine, homocysteine, and superoxide anion.Science advances · 2025Article
- Synthesis and Evaluation ofLife (Basel, Switzerland) · 2025Article
- AI in SPECT Imaging: Opportunities and Challenges.Seminars in nuclear medicine · 2025Review
- Feasibility study of multi Laue lens based SPECT with a dedicated 3D reconstruction algorithm using Monte Carlo simulations.Scientific reports · 2025Article
- Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.Journal of medicinal chemistry · 2025Review
- Molecular connectivity studies in neurotransmission: a scoping review.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with AlBioconjugate chemistry · 2024Article
- Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2024Review
- Revolutionizing Neurology: The Role of Artificial Intelligence in Advancing Diagnosis and Treatment.Cureus · 2024Review
- Molecules, Up Your Spins!Molecules (Basel, Switzerland) · 2024Article
- Deep learning-based PET image denoising and reconstruction: a review.Radiological physics and technology · 2024Review
- Fully automated radiosynthesis of [American journal of nuclear medicine and molecular imaging · 2024Article
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Automated radiosynthesis of [American journal of nuclear medicine and molecular imaging · 2024Article
- Article
- Deep-learning-based methods of attenuation correction for SPECT and PET.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Single photon emission computed tomography (SPECT) or positron emission computed tomography (PET) imaging agents for neurodegenerative diseases have a significant impact on clinical diagnosis and patient care. The examples of Parkinson's Disease (PD) and Alzheimer's Disease (AD) imaging agents described in this paper provide a general view on how imaging agents, i.e. radioactive drugs, are selected, chemically prepared and applied in humans. Imaging the living human brain can provide unique information on the pathology and progression of neurodegenerative diseases, such as AD and PD. The imaging method will also facilitate preclinical and clinical trials of new drugs offering specific information related to drug binding sites in the brain. In the future, chemists will continue to play important roles in identifying specific targets, synthesizing target-specific probes for screening and ultimately testing them by in vitro and in vivo assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.